Azacitidine successfully maintained the second remission in an infant with KMT2A‐rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation
The outcome for infants with KMT2A (MLL)‐rearranged acute lymphoblastic leukemia (MLL‐r ALL) is dismal despite intensive therapy, including hematopoietic stem cell transplantation (HSCT). Epigenetic dysregulation is considered a key driver of MLL‐r leukemogenesis, which theoretically supports the us...
Gespeichert in:
| Veröffentlicht in: | Pediatric blood & cancer 2017-12, Vol.64 (12), p.n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 12 |
| container_start_page | |
| container_title | Pediatric blood & cancer |
| container_volume | 64 |
| creator | Chijimatsu, Ikue Imanaka, Yusuke Tomizawa, Daisuke Eguchi, Mariko Nishimura, Shiho Karakawa, Shuhei Miki, Mizuka Hamamoto, Kazuko Fujita, Naoto |
| description | The outcome for infants with KMT2A (MLL)‐rearranged acute lymphoblastic leukemia (MLL‐r ALL) is dismal despite intensive therapy, including hematopoietic stem cell transplantation (HSCT). Epigenetic dysregulation is considered a key driver of MLL‐r leukemogenesis, which theoretically supports the use of epigenetic modifiers as a treatment option. We report an infant MLL‐r ALL case with post‐HSCT relapse. After achieving a second remission, which was maintained for 10 months using only the DNA methyltransferase inhibitor, azacitidine, the patient successfully received the second HSCT. This report describes the clinical effectiveness of azacitidine for the treatment of infant MLL‐r ALL. |
| doi_str_mv | 10.1002/pbc.26697 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1952197571</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1952197571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-8b7933aacef10d61fdd6a5a0e46f074f8aeea8657ec33ddb12744b3ea45e044e3</originalsourceid><addsrcrecordid>eNp1kU1u1DAYhi0EoqWw4ALIEisW09pxHCfLYcSfKIJFWUdf7M-MixMH29FoWPUIPQtH4iR4mNIdC_8_ft7FS8hzzs45Y9XFPOjzqmk69YCcclnLlWRcPbzfs-6EPEnpuqANk-1jclK1jZKNaE_Jr_VP0C474yakadEaU7KL93s6gptyGWho3pY31GEyNOLoUnJhom6icJgtTJnuXN7Sj5-uqvXvm9uIECNM38pP0EtG6vfjvA2Dh5Sdph6X78UCdLcNxedhTgfSZox0mQ4XuZx1iIYOPoQSX2Rp9iUHckl-Sh5Z8Amf3a1n5OvbN1eb96vLz-8-bNaXKy2kUKt2UJ0QABotZ6bh1pgGJDCsG8tUbVtAhLaRCrUQxgy8UnU9CIRaIqtrFGfk5dE7x_BjwZT767DEqUT2vJMV75RUvFCvjpSOIaWItp-jGyHue876Qzt9aaf_205hX9wZl2FEc0_-q6MAF0dg5zzu_2_qv7zeHJV_AH-rn6s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1952197571</pqid></control><display><type>article</type><title>Azacitidine successfully maintained the second remission in an infant with KMT2A‐rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chijimatsu, Ikue ; Imanaka, Yusuke ; Tomizawa, Daisuke ; Eguchi, Mariko ; Nishimura, Shiho ; Karakawa, Shuhei ; Miki, Mizuka ; Hamamoto, Kazuko ; Fujita, Naoto</creator><creatorcontrib>Chijimatsu, Ikue ; Imanaka, Yusuke ; Tomizawa, Daisuke ; Eguchi, Mariko ; Nishimura, Shiho ; Karakawa, Shuhei ; Miki, Mizuka ; Hamamoto, Kazuko ; Fujita, Naoto</creatorcontrib><description>The outcome for infants with KMT2A (MLL)‐rearranged acute lymphoblastic leukemia (MLL‐r ALL) is dismal despite intensive therapy, including hematopoietic stem cell transplantation (HSCT). Epigenetic dysregulation is considered a key driver of MLL‐r leukemogenesis, which theoretically supports the use of epigenetic modifiers as a treatment option. We report an infant MLL‐r ALL case with post‐HSCT relapse. After achieving a second remission, which was maintained for 10 months using only the DNA methyltransferase inhibitor, azacitidine, the patient successfully received the second HSCT. This report describes the clinical effectiveness of azacitidine for the treatment of infant MLL‐r ALL.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.26697</identifier><identifier>PMID: 28675638</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acute lymphoblastic leukemia ; Antimetabolites, Antineoplastic - therapeutic use ; azacitidine ; Azacitidine - therapeutic use ; Cord blood ; Cord Blood Stem Cell Transplantation ; DNA methyltransferase ; Epigenetics ; Gene Rearrangement ; Hematology ; Histone-Lysine N-Methyltransferase - genetics ; Humans ; Infant ; Infants ; KMT2A ; Leukemia ; Leukemogenesis ; Lymphatic leukemia ; Male ; MLL ; Myeloid-Lymphoid Leukemia Protein - genetics ; Oncology ; Pediatrics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics ; Recurrence ; Remission ; Stem cell transplantation ; Transplantation</subject><ispartof>Pediatric blood & cancer, 2017-12, Vol.64 (12), p.n/a</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-8b7933aacef10d61fdd6a5a0e46f074f8aeea8657ec33ddb12744b3ea45e044e3</citedby><cites>FETCH-LOGICAL-c3537-8b7933aacef10d61fdd6a5a0e46f074f8aeea8657ec33ddb12744b3ea45e044e3</cites><orcidid>0000-0003-4082-5595</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.26697$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.26697$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28675638$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chijimatsu, Ikue</creatorcontrib><creatorcontrib>Imanaka, Yusuke</creatorcontrib><creatorcontrib>Tomizawa, Daisuke</creatorcontrib><creatorcontrib>Eguchi, Mariko</creatorcontrib><creatorcontrib>Nishimura, Shiho</creatorcontrib><creatorcontrib>Karakawa, Shuhei</creatorcontrib><creatorcontrib>Miki, Mizuka</creatorcontrib><creatorcontrib>Hamamoto, Kazuko</creatorcontrib><creatorcontrib>Fujita, Naoto</creatorcontrib><title>Azacitidine successfully maintained the second remission in an infant with KMT2A‐rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation</title><title>Pediatric blood & cancer</title><addtitle>Pediatr Blood Cancer</addtitle><description>The outcome for infants with KMT2A (MLL)‐rearranged acute lymphoblastic leukemia (MLL‐r ALL) is dismal despite intensive therapy, including hematopoietic stem cell transplantation (HSCT). Epigenetic dysregulation is considered a key driver of MLL‐r leukemogenesis, which theoretically supports the use of epigenetic modifiers as a treatment option. We report an infant MLL‐r ALL case with post‐HSCT relapse. After achieving a second remission, which was maintained for 10 months using only the DNA methyltransferase inhibitor, azacitidine, the patient successfully received the second HSCT. This report describes the clinical effectiveness of azacitidine for the treatment of infant MLL‐r ALL.</description><subject>Acute lymphoblastic leukemia</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>azacitidine</subject><subject>Azacitidine - therapeutic use</subject><subject>Cord blood</subject><subject>Cord Blood Stem Cell Transplantation</subject><subject>DNA methyltransferase</subject><subject>Epigenetics</subject><subject>Gene Rearrangement</subject><subject>Hematology</subject><subject>Histone-Lysine N-Methyltransferase - genetics</subject><subject>Humans</subject><subject>Infant</subject><subject>Infants</subject><subject>KMT2A</subject><subject>Leukemia</subject><subject>Leukemogenesis</subject><subject>Lymphatic leukemia</subject><subject>Male</subject><subject>MLL</subject><subject>Myeloid-Lymphoid Leukemia Protein - genetics</subject><subject>Oncology</subject><subject>Pediatrics</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</subject><subject>Recurrence</subject><subject>Remission</subject><subject>Stem cell transplantation</subject><subject>Transplantation</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1u1DAYhi0EoqWw4ALIEisW09pxHCfLYcSfKIJFWUdf7M-MixMH29FoWPUIPQtH4iR4mNIdC_8_ft7FS8hzzs45Y9XFPOjzqmk69YCcclnLlWRcPbzfs-6EPEnpuqANk-1jclK1jZKNaE_Jr_VP0C474yakadEaU7KL93s6gptyGWho3pY31GEyNOLoUnJhom6icJgtTJnuXN7Sj5-uqvXvm9uIECNM38pP0EtG6vfjvA2Dh5Sdph6X78UCdLcNxedhTgfSZox0mQ4XuZx1iIYOPoQSX2Rp9iUHckl-Sh5Z8Amf3a1n5OvbN1eb96vLz-8-bNaXKy2kUKt2UJ0QABotZ6bh1pgGJDCsG8tUbVtAhLaRCrUQxgy8UnU9CIRaIqtrFGfk5dE7x_BjwZT767DEqUT2vJMV75RUvFCvjpSOIaWItp-jGyHue876Qzt9aaf_205hX9wZl2FEc0_-q6MAF0dg5zzu_2_qv7zeHJV_AH-rn6s</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Chijimatsu, Ikue</creator><creator>Imanaka, Yusuke</creator><creator>Tomizawa, Daisuke</creator><creator>Eguchi, Mariko</creator><creator>Nishimura, Shiho</creator><creator>Karakawa, Shuhei</creator><creator>Miki, Mizuka</creator><creator>Hamamoto, Kazuko</creator><creator>Fujita, Naoto</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0003-4082-5595</orcidid></search><sort><creationdate>201712</creationdate><title>Azacitidine successfully maintained the second remission in an infant with KMT2A‐rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation</title><author>Chijimatsu, Ikue ; Imanaka, Yusuke ; Tomizawa, Daisuke ; Eguchi, Mariko ; Nishimura, Shiho ; Karakawa, Shuhei ; Miki, Mizuka ; Hamamoto, Kazuko ; Fujita, Naoto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-8b7933aacef10d61fdd6a5a0e46f074f8aeea8657ec33ddb12744b3ea45e044e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acute lymphoblastic leukemia</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>azacitidine</topic><topic>Azacitidine - therapeutic use</topic><topic>Cord blood</topic><topic>Cord Blood Stem Cell Transplantation</topic><topic>DNA methyltransferase</topic><topic>Epigenetics</topic><topic>Gene Rearrangement</topic><topic>Hematology</topic><topic>Histone-Lysine N-Methyltransferase - genetics</topic><topic>Humans</topic><topic>Infant</topic><topic>Infants</topic><topic>KMT2A</topic><topic>Leukemia</topic><topic>Leukemogenesis</topic><topic>Lymphatic leukemia</topic><topic>Male</topic><topic>MLL</topic><topic>Myeloid-Lymphoid Leukemia Protein - genetics</topic><topic>Oncology</topic><topic>Pediatrics</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</topic><topic>Recurrence</topic><topic>Remission</topic><topic>Stem cell transplantation</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chijimatsu, Ikue</creatorcontrib><creatorcontrib>Imanaka, Yusuke</creatorcontrib><creatorcontrib>Tomizawa, Daisuke</creatorcontrib><creatorcontrib>Eguchi, Mariko</creatorcontrib><creatorcontrib>Nishimura, Shiho</creatorcontrib><creatorcontrib>Karakawa, Shuhei</creatorcontrib><creatorcontrib>Miki, Mizuka</creatorcontrib><creatorcontrib>Hamamoto, Kazuko</creatorcontrib><creatorcontrib>Fujita, Naoto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chijimatsu, Ikue</au><au>Imanaka, Yusuke</au><au>Tomizawa, Daisuke</au><au>Eguchi, Mariko</au><au>Nishimura, Shiho</au><au>Karakawa, Shuhei</au><au>Miki, Mizuka</au><au>Hamamoto, Kazuko</au><au>Fujita, Naoto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Azacitidine successfully maintained the second remission in an infant with KMT2A‐rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr Blood Cancer</addtitle><date>2017-12</date><risdate>2017</risdate><volume>64</volume><issue>12</issue><epage>n/a</epage><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>The outcome for infants with KMT2A (MLL)‐rearranged acute lymphoblastic leukemia (MLL‐r ALL) is dismal despite intensive therapy, including hematopoietic stem cell transplantation (HSCT). Epigenetic dysregulation is considered a key driver of MLL‐r leukemogenesis, which theoretically supports the use of epigenetic modifiers as a treatment option. We report an infant MLL‐r ALL case with post‐HSCT relapse. After achieving a second remission, which was maintained for 10 months using only the DNA methyltransferase inhibitor, azacitidine, the patient successfully received the second HSCT. This report describes the clinical effectiveness of azacitidine for the treatment of infant MLL‐r ALL.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28675638</pmid><doi>10.1002/pbc.26697</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-4082-5595</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2017-12, Vol.64 (12), p.n/a |
| issn | 1545-5009 1545-5017 |
| language | eng |
| recordid | cdi_proquest_journals_1952197571 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Acute lymphoblastic leukemia Antimetabolites, Antineoplastic - therapeutic use azacitidine Azacitidine - therapeutic use Cord blood Cord Blood Stem Cell Transplantation DNA methyltransferase Epigenetics Gene Rearrangement Hematology Histone-Lysine N-Methyltransferase - genetics Humans Infant Infants KMT2A Leukemia Leukemogenesis Lymphatic leukemia Male MLL Myeloid-Lymphoid Leukemia Protein - genetics Oncology Pediatrics Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Recurrence Remission Stem cell transplantation Transplantation |
| title | Azacitidine successfully maintained the second remission in an infant with KMT2A‐rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T17%3A08%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Azacitidine%20successfully%20maintained%20the%20second%20remission%20in%20an%20infant%20with%20KMT2A%E2%80%90rearranged%20acute%20lymphoblastic%20leukemia%20who%20relapsed%20after%20unrelated%20cord%20blood%20transplantation&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Chijimatsu,%20Ikue&rft.date=2017-12&rft.volume=64&rft.issue=12&rft.epage=n/a&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.26697&rft_dat=%3Cproquest_cross%3E1952197571%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1952197571&rft_id=info:pmid/28675638&rfr_iscdi=true |